Arcus Biosciences, Inc. (RCUS)
18.19
-0.42
(-2.26%)
USD |
NYSE |
Oct 30, 16:00
18.18
-0.02
(-0.08%)
After-Hours: 20:00
Arcus Biosciences Price to Book Value : 4.979 for Oct. 30, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 4.979 |
| October 29, 2026 | 5.094 |
| October 28, 2026 | 5.034 |
| October 27, 2026 | 4.965 |
| October 26, 2026 | 4.861 |
| October 23, 2026 | 5.074 |
| October 22, 2026 | 5.299 |
| October 21, 2026 | 5.228 |
| October 20, 2026 | 6.500 |
| October 19, 2026 | 6.060 |
| October 16, 2026 | 6.054 |
| October 15, 2026 | 6.246 |
| October 14, 2026 | 6.167 |
| October 13, 2026 | 6.161 |
| October 12, 2026 | 6.662 |
| October 09, 2026 | 6.681 |
| October 08, 2026 | 6.522 |
| October 07, 2026 | 6.711 |
| October 06, 2026 | 6.646 |
| October 05, 2026 | 6.772 |
| October 02, 2026 | 6.689 |
| October 01, 2026 | 6.906 |
| September 30, 2026 | 7.070 |
| September 29, 2026 | 7.021 |
| September 28, 2026 | 6.845 |
| Date | Value |
|---|---|
| September 25, 2026 | 6.834 |
| September 24, 2026 | 6.859 |
| September 23, 2026 | 7.223 |
| September 22, 2026 | 7.354 |
| September 21, 2026 | 7.103 |
| September 18, 2026 | 6.908 |
| September 17, 2026 | 6.990 |
| September 16, 2026 | 6.747 |
| September 15, 2026 | 6.657 |
| September 14, 2026 | 6.588 |
| September 11, 2026 | 6.730 |
| September 10, 2026 | 7.157 |
| September 09, 2026 | 7.798 |
| September 08, 2026 | 7.954 |
| September 04, 2026 | 8.118 |
| September 03, 2026 | 8.247 |
| September 02, 2026 | 8.170 |
| September 01, 2026 | 8.132 |
| August 31, 2026 | 8.014 |
| August 28, 2026 | 7.995 |
| August 27, 2026 | 8.373 |
| August 26, 2026 | 8.419 |
| August 25, 2026 | 8.641 |
| August 24, 2026 | 8.244 |
| August 21, 2026 | 8.304 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Halozyme Therapeutics, Inc. | 104.00 |
| AVITA Medical, Inc. | -- |
| Iovance Biotherapeutics, Inc. | 5.219 |
| Editas Medicine, Inc. | 3.894 |
| Recursion Pharmaceuticals, Inc. | 2.352 |
Price to Book Value Related Metrics
| PS Ratio | 18.52 |
| PEG Ratio | -0.2011 |
| Price | 18.19 |
| Earnings Yield | -21.46% |
| Market Cap | 2.310B |
| PEGY Ratio | -0.2011 |